Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
1372278 | Bioorganic & Medicinal Chemistry Letters | 2013 | 8 Pages |
Abstract
A virtual screening approach using various in silico methodologies led to the discovery of 2-(m-tolylamino)-7,8-dihydroquinazolin-5(6H)-one (1) as a moderately active negative allosteric modulator (NAM) of the metabotropic glutamate receptor subtype 5 (mGluR5) showing high selectivity against the subtype mGluR1. Modifications of the parent compound by rational design yielded a series of highly potent derivatives which will serve as valuable starting points for further hit-to-lead optimization efforts toward a suitable drug candidate for the treatment of l-DOPA induced dyskinesia.
Graphical abstractFigure optionsDownload full-size imageDownload as PowerPoint slide
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Holger Kubas, Udo Meyer, Bjoern Krueger, Mirko Hechenberger, Maksims Vanejevs, Ronalds Zemribo, Valerjans Kauss, Raisa Ambartsumova, Ilya Pyatkin, Alexey I. Polosukhin, Ulrich Abel,